Clinical Trial Update: Study Evaluating Pharmacovigilance Of Refacto AF

View source ↗

Summary

A completed pharmacovigilance study evaluating Refacto AF in Hemophilia A; results were posted on 2018-07-17.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Refacto AF (Factor VIII, recombinant)

Snippet

Sponsor: Pfizer | Conditions: Hemophilia A | Status: COMPLETED | Results posted: 2018-07-17